Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.
about
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesImmunotherapy advances for glioblastomaAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaHonokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell functionCombining cytotoxic and immune-mediated gene therapy to treat brain tumorsGLI2 regulates TGF-β1 in human CD4+ T cells: implications in cancer and HIV pathogenesis.Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain.Progress in active-specific immunotherapy of brain malignancies.Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape.Overview of cellular immunotherapy for patients with glioblastoma.Therapeutic activity of NK cells against tumors.Mechanisms of malignant glioma immune resistance and sources of immunosuppressionAll in the head: obstacles for immune rejection of brain tumours.Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.GBM Derived Gangliosides Induce T Cell Apoptosis through Activation of the Caspase Cascade Involving Both the Extrinsic and the Intrinsic Pathway.Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials.An Eighteen Serum Cytokine Signature for Discriminating Glioma from Normal Healthy Individuals.An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.Cytokine gene therapy for malignant glioma.Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors.Immunosuppressive mechanisms in glioblastoma.Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.Immunotherapy for malignant glioma: current approaches and future directions.Immunotherapy for human glioma: innovative approaches and recent results.Emerging immunotherapies for glioblastomaThe role of microglia in central nervous system immunity and glioma immunologyImmunotherapeutic approaches for gliomaCharacterization of distinct immunophenotypes across pediatric brain tumor types.Role of inflammation and oxidative stress mediators in gliomas.Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymomaThe application of Toll like receptors for cancer therapy.Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas.The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment.Vaccine-based immunotherapeutic approaches to gliomas and beyond.Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.Neural stem cell-based gene therapy for brain tumors.Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia while improving their susceptibility to lymphocyte-mediated cytotoxicity.The effects of systemic and intratumoral interleukin-12 treatment in C6 rat glioma model.Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma.
P2860
Q26798402-3828592A-4ABF-4FDA-9D31-EDDD259DFD3FQ26866513-80961412-30DD-4BB7-9BF1-978A5D9CE408Q27024830-5228CD51-CA99-40C0-9A46-A52BC3A1B7EFQ28246944-A9AE6078-B637-4C67-A0B5-4114749AC830Q31013320-981C6522-4927-4442-B237-0E6D15776DECQ31079257-2A9AF505-5230-4F4A-A382-91822F8CE257Q31148056-746E6AE1-B1AC-428F-B799-3E0A10474612Q34075068-0561D82C-05F4-464D-BE13-D780DB32011CQ34136498-8E21AC3B-A88A-4D6F-9BEB-28BC6F93CBB3Q34189694-8557C481-1B67-450A-9EB8-3E43C472CFC1Q34552162-A380CD85-569F-4711-B489-A54F57112A40Q34661793-8B1A01D1-88BC-4336-B408-E87F48F0E7EDQ34842204-7E9FAACD-1241-4E71-9421-4A3E138D27CEQ35113661-758AFDB5-9D83-434A-BB36-83FA5D221F3FQ35726496-34CFFD09-69A8-401E-9335-D0957603F2DCQ35778581-74100835-EE0F-44EC-A981-CF6267C9D552Q35781959-F1940BE5-4986-4D7A-8DEE-C2EBDB82FD67Q35800650-D914DAA4-5200-4C6A-B9AF-928EAF9F51EBQ35907022-3404AD25-9D8D-44A7-AB7E-28DAEA7D901BQ36139736-F24A7321-15A9-4C33-9F2D-1908AF7864A9Q36224048-30FB5C54-6C89-47CE-9840-E8F935C64AB4Q36224057-48422EF9-6AC5-4620-A5CC-3788752283FBQ36273693-B3436E7F-3BD5-4FFF-BB44-F6553481E996Q36284489-7027FA60-87E7-4CF9-B299-BC41FF101CF2Q37025105-89E2FC16-4A1B-4408-9074-F95EB4A346F1Q37206898-098458D3-9FF9-40BD-A631-D98F4F238DFAQ37267793-AAC51307-33A0-423D-9642-1F3F16410DD9Q37308164-7C6419A2-199E-44D3-BABE-A6E992FC118CQ37328326-D7B114B3-0791-4034-A1E0-9596A62CD10CQ37705192-D8A3C867-9B5E-4170-A3E0-4B274B4D356AQ37808111-614BA943-C34E-41C8-976E-C6703B24B90CQ37952245-56D0106D-4C99-4C6F-A7CB-3BF2FEC735A2Q38614374-9F506A8A-B895-4640-B556-9928ED464ED1Q38789860-587D2FAB-6704-4FAC-8585-FB7314588216Q38989773-258017C2-FF3C-4502-BDDA-DC17DC003AA3Q39137284-3DEE05A9-BB98-4C17-9631-D49D3860D9E0Q39686208-192E30C5-645E-4C51-BBBF-8568A1DCF3DEQ39924722-5B2B3132-86B1-4CC8-9D95-925343C9DA94Q40485606-D5A56026-BE84-48A4-BC0E-959E8D2A06CEQ40639515-5688CCC6-719A-427F-82FD-A666EC8E3E04
P2860
Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.
@en
type
label
Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.
@en
prefLabel
Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.
@en
P2093
P2860
P1433
P1476
Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.
@en
P2093
P2860
P304
1160-6; discussion 1166-7
P356
10.1227/00006123-199512000-00016
P407
P577
1995-12-01T00:00:00Z